Literature DB >> 7199922

Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients.

J G Leferink, W van den Berg, I Wagemaker-Engels, J Kreukniet, R A Maes.   

Abstract

The pharmacokinetics of 1-(35-dihydroxyphenyl)-2-(tert.butylamino)ethanol (terbutaline, Bricanyl) after i.v. and s.c. injection to normal humans and after s.c. and p.o. administration to patients was studied. The kinetic measurements showed that the standard deviations of the respective parameters were not excessively large. Therefore a reasonable production of the behaviour of terbutaline in man is possible. Some important parameters are the biological half-life at 3.6 h (SD = 1.0), the body clearance at 0.26 l/(kg x h) (SD = 0.09), the volume of the reference compartment at 0.47 l/kg (SD = 0.10) and the volume in the steady state at 1.01 l/kg (SD = 0.14). The absolute bioavailability is calculated at 10%.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7199922

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  9 in total

1.  The influence of assay variability on pharmacokinetic parameter estimation.

Authors:  D A Graves; C S Locke; K T Muir; R P Miller
Journal:  J Pharmacokinet Biopharm       Date:  1989-10

2.  Negative power functions of time in pharmacokinetics and their implications.

Authors:  M E Wise
Journal:  J Pharmacokinet Biopharm       Date:  1985-06

3.  The effect of pH and organic ester penetration enhancers on skin permeation kinetics of terbutaline sulfate from pseudolatex-type transdermal delivery systems through mouse and human cadaver skins.

Authors:  Lalatendu Panigrahi; Snigdha Pattnaik; Saroj K Ghosal
Journal:  AAPS PharmSciTech       Date:  2005-09-30       Impact factor: 3.246

4.  Pharmacodynamic modelling of the drug-induced downregulation of a beta 2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone.

Authors:  R E Jonkers; M C Braat; R P Koopmans; C J van Boxtel
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 5.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

6.  A comparison of the clinical and bronchodilating effects of plain and slow-release tablets of terbutaline at steady state.

Authors:  R Pauwels; W Elinck; H Lamont; M van der Straeten; K Ljungholm
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

Review 7.  Pharmacokinetic optimisation of asthma treatment.

Authors:  A M Taburet; B Schmit
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

8.  A novel nanogel loaded with chitosan decorated bilosomes for transdermal delivery of terbutaline sulfate: artificial neural network optimization, in vitro characterization and in vivo evaluation.

Authors:  Shahira F El Menshawe; Heba M Aboud; Mohammed H Elkomy; Rasha M Kharshoum; Amany M Abdeltwab
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

Review 9.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.